---
title: "Metodi di Psicofisiologia e Neuroimaging nella Clinica e nelle Neuroscienze Cognitive"
subtitle: "Translational Biomarkers"
author: "Raffaele M Mazziotti, PhD"
institute: "University of Florence"
resources:
  - quiz/
  - images/
format:
  revealjs:
    controls: true
    theme: default
    slide-number: true
    logo: images/logo/NEUROFARBA_logo.svg
    css: slide_style.css
    transition: fade
    center: true
    math: mathjax
    chalkboard: 
      buttons: false
    progress: true
    title-slide-attributes:
      data-background-image: images/logo/NEUROFARBA.svg
      data-background-size: 500px
      data-background-position: "center 10%"
      data-state: title-slide
    include-after-body: afterbody.html
    mermaid:
      theme: neutral
    
---

## Translational `biomarkers`

:::columns
:::column

:::info-box
A translational `biomarker` is a measurement that:

- `quantifies` a biological process linked to a disorder
- is `repeatable` across sessions and sites
- can be measured in both `models` and `patients`

:::

:::info-box
Typical outputs you can bring into trials:

- diagnostic / stratification feature
- pharmacodynamic marker
- mechanism-linked readout (helps interpret "why" a treatment works)

:::

:::
:::column

:::info-box
What to do (a practical checklist):

- define the `construct` (what brain function you are indexing)
- choose a readout with high `reliability`
- test `developmental` sensitivity 
- test `treatment` sensitivity 
- report effect size + cross-validated `prediction` 

A biomarker must be `deployable`, not only significant.

:::

:::
:::

## Neurodevelopmental disorders as `critical period` disorders

:::columns
:::column

:::info-box
A key theoretical proposal:

Some neurodevelopmental disorders may reflect disruptions of `critical periods`.

If maturation is altered during these windows:

- circuit refinement may be incomplete or mistimed
- long-term functional deficits emerge
- later interventions may have reduced efficacy

This shifts focus from static deficit → altered developmental trajectory.
:::

:::
:::column

:::info-box
Why this matters clinically:

If disorders involve altered `critical period` timing, then we need biomarkers that:

- detect dysfunction `early`
- track developmental trajectories
- are sensitive to maturation dynamics
- can monitor reopening or rescue of plasticity

:::

:::
:::

## Why `visual cortex` is ideal for critical period biomarkers

:::columns
:::column

:::info-box
Primary visual cortex (`V1`) is one of the best-characterized critical period systems:

- well-defined sensory input
- precisely mapped circuitry
- known developmental windows
- measurable plasticity

Its maturation can be tracked quantitatively using:

- `ISI` & `fNIRS` imaging
- `VEP`


This makes V1 a natural testbed for developmental biomarkers.
:::

:::
:::column

:::info-box
If a disorder alters `critical period` timing or gain we expect to observe:

- abnormal emergence of evoked responses
- altered amplitude or tuning
- reduced experience-dependent plasticity
- persistent deficits into adulthood

Therefore, evoked V1 responses can serve as:

- early `detection` markers
- mechanistic indicators of circuit maturation
- potential pharmacodynamic endpoints

:::

:::
:::

## Why `arousal` is also linked to critical periods

:::columns
:::column

:::info-box
Neuromodulators regulate plasticity:

- `acetylcholine`
- `norepinephrine`

These systems:

- gate cortical responsiveness
- modulate signal-to-noise
- influence experience-dependent refinement

Arousal state is therefore not just behavioral, it shapes developmental plasticity.
:::

:::
:::column

:::info-box
If neuromodulatory tone is altered:

- critical period dynamics may shift
- plasticity thresholds may change
- circuit refinement may be impaired

`Pupil` and `HRV` provide scalable readouts of these systems.

Thus arousal biomarkers may index a mechanism that directly impacts developmental timing.
:::

:::
:::

## CDKL5 Deficiency Disorder (CDD)

::: {.disorder-card}
<div class="disorder-header">
  <div class="disorder-title">CDKL5 Deficiency Disorder (CDD)</div>
  <div class="disorder-subtitle">A severe developmental epileptic encephalopathy caused by loss-of-function variants in `CDKL5`</div>
</div>

<div class="disorder-body">

**Cause**
- pathogenic variants in the `CDKL5` gene (X-linked)
- impacts neurodevelopmental signaling and circuit maturation

**Core clinical picture**
- early-onset seizures (often in infancy)
- global developmental delay and intellectual disability
- motor impairment and hypotonia; often limited speech
- frequent comorbidities: sleep, feeding, autonomic dysregulation

**Why biomarkers matter**
- symptoms are heterogeneous and change over development
- clinical trials need objective, repeatable functional endpoints beyond caregiver report

</div>
:::

## Why CDD is ideal for `V1` + `arousal` biomarkers

:::columns
:::column

:::info-box
CDD has strong rationale for `visual cortex` endpoints:

- early circuit maturation is disrupted
- sensory systems show measurable developmental trajectories
- evoked responses can reveal when deficits emerge

This supports an early, longitudinal biomarker strategy.
:::

:::
:::column

:::info-box
CDD also fits an `arousal` biomarker strategy:

- widespread neuromodulatory and autonomic involvement is plausible
- arousal regulation can be measured without demanding tasks
- passive measures support severe disability cohorts

This supports scalable endpoints for monitoring and stratification.
:::

:::
:::

## Experiment: Early `V1` impairment in CDKL5 mice

::: {.experiment-card}
<div class="exp-header" style="display:flex; justify-content:space-between; align-items:center;">
<span>Intrinsic Optical Signal Imaging and VEPs</span>
<a href="https://doi.org/10.1093/hmg/ddx119" target="_blank"
   style="font-size:0.65em; padding:3px 8px; border:1px solid rgba(200,200,200,0.5); border-radius:8px; text-decoration:none;">
Reference
</a>
</div>

<div class="exp-section">

:::columns
:::column
<div class="exp-section-title">Method</div>

- longitudinal transcranial `IOS` during development  
- repeated recordings across a developmental window  
- `VEP` recordings for validation  
- phenotype summarized with multi-feature classification (`SVM`)  

:::

:::column
<div class="exp-section-title">Key results</div>

- developmental emergence of reduced evoked visual responses  
- deficit persists into later ages  
- early measures discriminate genotype with high accuracy  

:::
:::

</div>

:::

## Experiment: Early `V1` impairment in CDKL5 mice

:::columns
:::column

![](images/biotrans_ios_pipe.png){width="400" fig-align="center"}

![](images/biotrans_cdkl5_ios.jpeg){width="400" fig-align="center"}

:::
:::column

![](images/biotrans_cdkl5_vep.jpeg){width="400" fig-align="center"}
![](images/biotrans_cdkl5_pca.jpeg){width="500" fig-align="center"}

:::
:::

## CDKL5: from model to patient

:::columns
:::column

:::info-box
Preclinical evidence showed:

- developmental impairment of `V1` evoked responses
- stable circuit-level deficit
- strong genotype discrimination

But translational relevance requires confirmation in `patients`.
:::

:::
:::column

:::info-box
Key question:

Do individuals with CDKL5 show measurable `visual evoked` abnormalities?

And crucially:

Do physiological measures correlate with `clinical severity`?

If yes → the animal biomarker has clinical validity.
:::

:::
:::

---

## Experiment: Visual evoked potentials in CDKL5 patients

::: {.experiment-card}
<div class="exp-header" style="display:flex; justify-content:space-between; align-items:center;">
<span>Visual Evoked Potentials and Clinical Severity in CDKL5</span>
<a href="https://www.sciencedirect.com/science/article/pii/S0022510X24001989" target="_blank"
   style="font-size:0.65em; padding:3px 8px; border:1px solid rgba(200,200,200,0.5); border-radius:8px; text-decoration:none;">
Reference
</a>
</div>

<div class="exp-section">

:::columns
:::column
<div class="exp-section-title">Method</div>

- record `VEP` responses in individuals with CDKL5  
- quantify amplitude and latency parameters  
- assess relationship with standardized clinical severity scales  

:::

:::column
<div class="exp-section-title">Key results</div>

- altered `VEP` responses compared to controls  
- physiological parameters correlate with `clinical severity`  
- stronger impairment associated with more severe phenotype  

:::
:::

</div>

<div class="exp-section">
<div class="exp-section-title">Translational significance</div>

- confirms that `V1` dysfunction is present in patients  
- validates the mouse `V1` phenotype as clinically relevant  
- supports evoked visual responses as a potential `trial endpoint`  

</div>

:::

## Experiment: Visual evoked potentials in CDKL5 patients

![](images/biotrans_cdkl5_correlation.jpg){width="200" fig-align="center"}

:::card
Correlation between the amplitude of VEP P100 and the CDKL5 Deficiency disorder - Severity Assessment (CDD-SA) 
<a href="https://doi.org/10.1016/j.jns.2024.123063" target="_blank"
   style="font-size:0.65em; padding:3px 8px; border:1px solid rgba(200,200,200,0.5); border-radius:8px; text-decoration:none;">
Reference
</a>
:::

## Experiment: `Arousal` dysregulation in CDKL5 mice

::: {.experiment-card}
<div class="exp-header" style="display:flex; justify-content:space-between; align-items:center;">
<span>Operant behavior + pupillometry + machine learning</span>
<a href="https://doi.org/10.1093/hmg/ddac164" target="_blank"
   style="font-size:0.65em; padding:3px 8px; border:1px solid rgba(200,200,200,0.5); border-radius:8px; text-decoration:none;">
Reference
</a>
</div>

<div class="exp-section">

:::columns
:::column
<div class="exp-section-title">Method</div>

- operant task to probe cognition/strategy  
- simultaneous `pupil` recording and locomotor monitoring  
- supervised `ML` to classify genotype from multimodal features  

:::

:::column
<div class="exp-section-title">Key results</div>

- altered tonic pupil dynamics and stimulus-evoked pupil responses  
- atypical coupling between pupil state and locomotion  
- multimodal features improve genotype discrimination  

:::
:::

</div>

:::

## Experiment: `Arousal` dysregulation in CDKL5 mice
:::columns
:::column

![](images/biotrans_cdkl5_pup_data.png){width="400" fig-align="center"}
![](images/biotrans_cdkl5_pup_orienting.png){width="300" fig-align="center"}

:::
:::column

![](images/biotrans_cdkl5_pup_table.png){width="800" fig-align="center"}

:::
:::

## Experiment: Deep learning of spontaneous `arousal` dynamics (cross-model → patient)

::: {.experiment-card}
<div class="exp-header" style="display:flex; justify-content:space-between; align-items:center;">
<span>Deep learning on spontaneous pupil dynamics + transfer to HRV</span>
<a href="https://doi.org/10.1073/pnas.1820847116" target="_blank"
   style="font-size:0.65em; padding:3px 8px; border:1px solid rgba(200,200,200,0.5); border-radius:8px; text-decoration:none;">
Reference
</a>
</div>

<div class="exp-section">

:::columns
:::column
<div class="exp-section-title">Method</div>

- collect spontaneous `pupil` fluctuations across ASD-related mouse models  
- train a convolutional network to decode arousal-related temporal signatures  
- apply transfer learning to human physiological data (`HRV`)  

:::

:::column
<div class="exp-section-title">Key results</div>

- identifies altered arousal signatures across models, including early stages  
- captures temporal structure beyond summary statistics  
- transfer learning supports discrimination in patient datasets  

:::
:::

</div>

:::

## Experiment: Deep learning of spontaneous `arousal` dynamics (cross-model → patient)

![](images/biotrans_pup_artoni.png){width="400" fig-align="center"}

## Creatine Transporter Deficiency (CTD)

::: {.disorder-card}
<div class="disorder-header">
  <div class="disorder-title">Creatine Transporter Deficiency (CTD)</div>
  <div class="disorder-subtitle">Loss of function in `SLC6A8` → impaired creatine transport → neurodevelopmental impairment</div>
</div>

<div class="disorder-body">

**Cause**
- pathogenic variants in `SLC6A8` (X-linked)
- reduced creatine availability in brain → altered energy buffering

**Core clinical picture**
- global developmental delay and intellectual disability
- speech and motor impairment; behavioral dysregulation
- seizures can occur; autistic-like features are common

**Why biomarkers matter**
- trials need objective endpoints that track brain function over time
- a strong biomarker should be `treatment-sensitive` and repeatable

</div>
:::

## Experiment: CTD Translational phenotype

::: {.experiment-card}
<div class="exp-header" style="display:flex; justify-content:space-between; align-items:center;">
<span>Shared EEG network alterations (mouse ↔ patient)</span>
<a href="https://doi.org/10.1093/braincomms/fcaa089" target="_blank"
   style="font-size:0.65em; padding:3px 8px; border:1px solid rgba(200,200,200,0.5); border-radius:8px; text-decoration:none;">
Reference
</a>
</div>

<div class="exp-section">

:::columns
:::column
<div class="exp-section-title">Method</div>

- EEG & ISI in CTD mouse model  
- EEG in individuals with CTD  
- oscillatory + network metrics  
- quantitative comparison  

:::

:::column
<div class="exp-section-title">Key results</div>

- abnormal ISI and cortical oscillations in mice  
- overlapping EEG alterations in patients
- objective cross-species signature  

:::
:::

</div>

:::

## Experiment: CTD Translational phenotype
![](images/biotrans_ctd_eeg.png){width="500" fig-align="center"}

## Experiment: CTD Translational phenotype
![](images/biotrans_ctd_ios.png){width="500" fig-align="center"}

## Experiment: CTD Translational phenotype
![](images/biotrans_ctd_model.png){width="500" fig-align="center"}

## From `IOS` to `fNIRS`

:::columns
:::column

:::info-box
In CTD mice we identified:

- robust `V1` hemodynamic deficits  
- strong WT vs KO separation  
- longitudinal sensitivity  

This established a reliable `visual cortex biomarker`.
:::

:::
:::column

:::info-box
Translational question:

How do we bring this to `children`?

Constraints:

- non-invasive  
- tolerant to movement  
- feasible in pediatric populations  

Solution: adopt `fNIRS` as human analog of IOS.
:::

:::
:::

---

## Why `fNIRS` for pediatric translation?

:::columns
:::column

:::info-box
`fNIRS` measures:

- changes in `HbO`
- changes in `HbR`
- total hemoglobin (`THb`)

It is:

- portable  
- quiet  
- child-friendly  
- suitable for repeated sessions  

:::

:::
:::column

:::info-box
Challenge:

- hemodynamic signal is `slow`
- children have limited attention span
- traditional checkerboards are boring

Therefore, stimulus design becomes critical.
:::

:::
:::

---

## Developing a child-friendly visual paradigm

:::columns
:::column

:::info-box
Problem:

Standard reversing checkerboard blocks are:

- repetitive  
- low engagement  
- difficult for long pediatric recordings  

We needed a stimulus that was:

- visually strong  
- engaging  
- compatible with block design  

:::

:::
:::column

:::info-box
Solution:

- embed checkerboard into animated `cartoon` content  
- maintain contrast reversals  
- preserve visual drive  
- increase compliance  

Goal: maximize `signal` without losing attention.
:::

:::
:::

---

## Developing a child-friendly visual paradigm
:::columns
:::column

![](images/biotrans_peppa.mp4){width="400" fig-align="center"}

:::
:::column

![](images/biotrans_nemo.mp4){width="400" fig-align="center"}

:::
:::

## Experiment: Cartoon-based `fNIRS` visual paradigm

::: {.experiment-card}
<div class="exp-header" style="display:flex; justify-content:space-between; align-items:center;">
<span>Occipital fNIRS during engaging visual stimulation</span>
<a href="https://doi.org/10.1038/s41398-022-01820-5" target="_blank"
   style="font-size:0.65em; padding:3px 8px; border:1px solid rgba(200,200,200,0.5); border-radius:8px; text-decoration:none;">
Reference
</a>
</div>

<div class="exp-section">

:::columns
:::column
<div class="exp-section-title">Method</div>

- occipital `fNIRS` recordings  
- reversing checkerboard blended with cartoon animation  
- block design optimized for children  
- tested in typically developing cohort  

:::

:::column
<div class="exp-section-title">Key results</div>

- robust visual hemodynamic response  
- high compliance and low dropout  
- strong `THb` and `HbO` modulation  
- reproducible across participants  

:::
:::

</div>

:::

## Visual `fNIRS` amplitude and autistic traits

:::columns
:::column

:::info-box
In the typical population we observed:

- variability in visual hemodynamic amplitude  
- stable individual differences  

We then tested association with:

- quantitative `autistic traits`  

:::

:::
:::column

:::info-box
Key finding:

- lower `THb` response amplitude  
- associated with higher autistic trait scores  

Implication:

Visual cortical response amplitude may reflect  
a dimensional neurodevelopmental phenotype.
:::

:::
:::

## Visual `fNIRS` amplitude and autistic traits

![](images/biotrans_fnirs_asd_traits.png){width="400" fig-align="center"}

## Converging autism evidence

:::columns
:::column

:::info-box
In typically developing children:

- lower visual `THb` amplitude  
- associated with higher autistic traits  

Dimensional phenotype.
:::

:::
:::column

:::info-box
In diagnosed female ASD:

- reduced `OHb` amplitude  
- altered hemispheric lateralization  
- correlation with `AQ` severity  

Clinical phenotype.
:::

:::
:::

## Experiment: Visual `fNIRS` in female preschoolers with ASD

::: {.experiment-card}
<div class="exp-header" style="display:flex; justify-content:space-between; align-items:center;">
<span>Cartoon-based visual fNIRS in fASD preschoolers</span>
<a href="https://doi.org/10.3390/brainsci13060951" target="_blank"
   style="font-size:0.65em; padding:3px 8px; border:1px solid rgba(200,200,200,0.5); border-radius:8px; text-decoration:none;">
Reference
</a>
</div>

<div class="exp-section">

:::columns
:::column
<div class="exp-section-title">Method</div>

- high-functioning female preschoolers with ASD  
- age-matched TD controls  
- occipital `fNIRS` during cartoon-based checkerboard  
- extract `THb`, `OHb`, `DHb`  
- compute `laterality index`  

:::

:::column
<div class="exp-section-title">Key results</div>

- reliable visual response in both groups  
- significantly lower `OHb` amplitude in ASD  
- reduced rightward lateralization  
- atypical hemispheric coupling  
- laterality correlates with `AQ` severity  

:::
:::

</div>

:::


## Experiment: Visual `fNIRS` in female preschoolers with ASD

:::columns
:::column

![](images/biotrans_fnirs_asd.png){width="400" fig-align="center"}

:::
:::column

![](images/biotrans_fnirs_asd_laterality.png){width="400" fig-align="center"}


:::
:::
